TY - JOUR
T1 - Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells
AU - Meng, Tzu Ching
AU - Lee, Ming Shyue
AU - Lin, Ming Fong
N1 - Funding Information:
We thank Dr Hsing-Jien Kung for his gift of pCMV-HER2 plasmid, Dr Chawnshang Chang for anti-AR antiserum, Dr Robert Lewis for monoclonal anti-Myc tag antibody and Ms Fen-Fen Lin for the technical assistance of initial tissue culture works. This study was supported in part by a NIH grant CA72274, Nebraska Cancer and Smoking Diseases Research Program LB 506 grant #2000-19, UNMC Eppley Cancer Center grant LB 595 and BMB Prostate Cancer Research Program to M-F Lin and Graduate Study Fellowships from the Graduate Studies Oce, University of Nebraska Medical Center to T-C Meng and M-S Lee.
PY - 2000/5/18
Y1 - 2000/5/18
N2 - Steroid hormones play key roles in regulating cell proliferation and differentiation in targeting tissues. However, in advanced cancers, the steroid hormone regulation is frequently attenuated through a yet unknown mechanism even in the presence of functional steroid hormone receptors. We investigate the functional role of tyrosine phosphorylation signaling in the hormone-refractory growth of human prostate tumors. Initial studies demonstrate that the androgen-responsive phenotype of human prostate cancer cells associates with a low phosphotyrosine (p-Tyr) level of ErbB-2, which is regulated by cellular prostatic acid phosphatase (PAcP), a protein tyrosine phosphatase. In prostate cancer cells, the p-Tyr level, hut not the protein level, of ErbR-2 inversely correlates with the androgen-responsiveness of cell proliferation. Androgen-stimulated cell growth concurs with a down-regulation of cellular PAcP, an elevated p-Tyr level of ErbB-2, and the activation of mitogen-activated protein kinases. Furthermore, only the ErbB-2 inhibitor AG 879, but not the EGFR inhibitor AG 1478, abolishes androgen-induced cell proliferation. Forced expression of ErbB-2 can also attenuate androgen promotion of cell growth. Data taken collectively conclude that in human prostate cancer cells, the tyrosine phosphorylation of ErbB-2 regulated by cellular PAcP plays a key role in regulating androgen-mediated proliferation signaling.
AB - Steroid hormones play key roles in regulating cell proliferation and differentiation in targeting tissues. However, in advanced cancers, the steroid hormone regulation is frequently attenuated through a yet unknown mechanism even in the presence of functional steroid hormone receptors. We investigate the functional role of tyrosine phosphorylation signaling in the hormone-refractory growth of human prostate tumors. Initial studies demonstrate that the androgen-responsive phenotype of human prostate cancer cells associates with a low phosphotyrosine (p-Tyr) level of ErbB-2, which is regulated by cellular prostatic acid phosphatase (PAcP), a protein tyrosine phosphatase. In prostate cancer cells, the p-Tyr level, hut not the protein level, of ErbR-2 inversely correlates with the androgen-responsiveness of cell proliferation. Androgen-stimulated cell growth concurs with a down-regulation of cellular PAcP, an elevated p-Tyr level of ErbB-2, and the activation of mitogen-activated protein kinases. Furthermore, only the ErbB-2 inhibitor AG 879, but not the EGFR inhibitor AG 1478, abolishes androgen-induced cell proliferation. Forced expression of ErbB-2 can also attenuate androgen promotion of cell growth. Data taken collectively conclude that in human prostate cancer cells, the tyrosine phosphorylation of ErbB-2 regulated by cellular PAcP plays a key role in regulating androgen-mediated proliferation signaling.
KW - Androgen responsiveness
KW - ErbB-2
KW - Human prostate cancer
KW - Prostatic acid phosphatase
KW - Tyrosine phosphorylation
UR - http://www.scopus.com/inward/record.url?scp=0034682240&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034682240&partnerID=8YFLogxK
U2 - 10.1038/sj.onc.1203576
DO - 10.1038/sj.onc.1203576
M3 - Article
C2 - 10851066
AN - SCOPUS:0034682240
SN - 0950-9232
VL - 19
SP - 2664
EP - 2677
JO - Oncogene
JF - Oncogene
IS - 22
ER -